Deal Tracker · Companies

Faes Farma deals

2 deals involving Faes Farma (Spain) tracked by EPT across Global (LMICs) & Latin America, with partners including Dongkook Pharmaceutical & SIFI. Latest: Dongkook Pharmaceutical → Faes Farma (Licensing, 1 Jul 2026).

2
deals tracked
1
announced in 2026
$310m
disclosed value (1 deal)
50%
licensing, the top deal type
  • EPT has tracked 2 Faes Farma deals (2025–2026), 1 of them announced in 2026.
  • The most common structures are licensing (50%) & m&a (50%).
  • By region: Global (LMICs) (50%) & Latin America (50%).
  • Values were disclosed for 1 of 2 deals, totalling $310m; the largest is Faes Farma → SIFI ($310m, 2 Sept 2025).

Countries involved

Spain (2) · Italy (1) · South Korea (1) · Türkiye (1) · UAE (1)

Largest disclosed deals

Questions

How many Faes Farma deals has EPT tracked?
2 as of 1 Jul 2026, covering 2025–2026; 1 were announced in 2026. The most recent is Dongkook Pharmaceutical → Faes Farma (Licensing, 1 Jul 2026).
What types of Faes Farma deals are most common?
Licensing: 1 (50%); M&A / Acquisition: 1 (50%).
What is the largest disclosed Faes Farma deal?
Faes Farma → SIFI: $310m (M&A / Acquisition, 2 Sept 2025). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)